What Happened

The FDA approved gepirone ER (Exxua) in 2023 despite 4 prior rejections and only 2 of 12 trials showing statistical significance. A 2026 JAMA Psychiatry study revealed the drug's 0.5-point HAMD-17 improvement fell short of the 3-6 point threshold for clinical benefit.

Who Is Affected

Organon and Fabre-Kramer Pharmaceuticals face renewed scrutiny over Exxua's approval. Psychiatrists prescribing antidepressants may reconsider efficacy benchmarks, while payers could reassess formulary positions for marginal-efficacy drugs.

Market Impact

• Reps may encounter pushback on FDA-approved claims for other antidepressants
• Provider conversations shifting from "FDA-approved" to trial data scrutiny
• Potential EHR alert updates highlighting marginal-efficacy drugs

What to Watch

Monitor FDA response to JAMA study and any revised guidance on efficacy standards. Track if payers implement prior auth requirements for gepirone ER prescriptions. Watch for similar scrutiny on other narrowly-approved CNS drugs.